CLAIMS

What is claimed is:

A method of treating neurological-urological conditions in mammals comprising the step of administering a therapeutically effective amount of at least one neurotoxin.

I. The method according to claim 1, wherein the neurological-urological condition includes prostatic enlargement.

II. The method according to claim 2, wherein the mammal is human male.

4. The method of claim 2, wherein the prostatic enlargement is selected from the group consisting of benign prostatic hyperplasia, abacterial prostatitis and prostatodynia.

5. The method of claim 1, wherein the neurotoxin is selected from the group consisting of botulinum toxin, capsaicin, terodotoxin, resinoferatoxin and α-bungotoxin.

The method of claim 5, wherein the neurotoxin is Botulinum toxin type A.

III. The method of claim 5, wherein the Botulinum toxin type A is Botox.

IV. The method of claim 2, wherein the prostatic enlargement is benign prostatic hyperplasia.

V. The method of claim 1, wherein the neurological-urological condition is selected from the group consisting of pelvic pain (e.g., interstitial cystitis, endometriosis, prostatodynia, urethral instability syndromes), pelvic myofascial elements (e.g., levator sphincter, dysmenorrhea, anal fistula, hemorrhoid), urinary incontinence (e.g., unstable bladder, unstable sphincter), prostate disorders (e.g., BPH, prostate cancer), recurrent infection (secondary to sphincter spasticity), and urinary retention (secondary to spastic sphincter, hypertrophied bladder neck, and neurogenic bladder dysfunction (e.g., Parkinson's Disease, spinal cord injury, stroke, multiple sclerosis, spasm reflex) and other such urological conditions of a nervous etiology.